Holen Sie sich die Stockscreener-App
6.61
1.69%
0.11
Schlusskurs vom Vortag:
$6.50
Offen:
$6.55
24-Stunden-Volumen:
185.81K
Relative Volume:
0.77
Marktkapitalisierung:
$330.26M
Einnahmen:
$13.56M
Nettoeinkommen (Verlust:
$-26.97M
KGV:
-11.51
EPS:
-0.5742
Netto-Cashflow:
$-24.04M
1W Leistung:
-4.06%
1M Leistung:
+3.93%
6M Leistung:
-37.35%
1J Leistung:
+0.00%
1-Tages-Spanne:
$6.41
$6.725
1-Wochen-Bereich:
$6.335
$7.40
52-Wochen-Spanne:
$3.4341
$15.37
Capsovision Inc Stock (CV) Company Profile
Firmenname
Capsovision Inc
Sektor
Branche
Telefon
(408) 370-4790
Adresse
18805 COX AVENUE SUITE 250, SARATOGA
Compare CV vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CV
Capsovision Inc
|
6.61 | 330.26M | 13.56M | -26.97M | -24.04M | -0.5742 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Capsovision Inc Stock (CV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-28 | Eingeleitet | Roth Capital | Buy |
| 2025-07-28 | Eingeleitet | The Benchmark Company | Speculative Buy |
Capsovision Inc Aktie (CV) Neueste Nachrichten
CapsoVision Inc (CV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CapsoVision Inc (CV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CapsoVision prices $27.5M IPO - MSN
CapsoVision Inc (CV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CapsoVision Inc (CV) Valuation: PE, PB & Fair Value Analysis - TradingKey
CapsoVision Inc (CV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CapsoVision Inc (CV) Institutional Confidence - TradingKey
CapsoVision Inc (CV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CapsoVision Inc (CV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CapsoVision Inc (CV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CV | CapsoVision, Inc. Common Stock Insider Trading - Quiver Quantitative
CapsoVision shareholders re-elect directors and approve auditor at annual meeting - Investing.com
CapsoVision Stockholders Reelect Directors, Ratify 2026 Auditor - TipRanks
CapsoVision Inc. (CV) Declines 2.5% as Bearish Pressure Builds Near Key SupportCumulative Volume - newsline.com
CapsoVision Inc. (CV) Q1 2026 Earnings: EPS Miss Exceeds Estimates, Stock DeclinesPost-Earnings Reaction - newsline.com
CapsoVision Inc. (CV) Q1 2026 Earnings: Wider-than-Expected Loss Weighs on SharesRevenue Miss Report - newsline.com
CapsoVision Inc. (CV) Faces Selling Pressure as Shares Slide Over 4.6%Triangle Correction - newsline.com
CV Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue PhaseTax Rate Impact - newsline.com
CapsoVision Inc. (CV) Q1 2026 Earnings: EPS Miss Widens Losses, Stock DeclinesRevenue Inflection Point - newsline.com
CapsoVision (CV) awards 158,078 options to Head of Global Sales - Stock Titan
CV News | CAPSOVISION INC (NASDAQ:CV) - ChartMill
CV Q1 2026 Earnings: EPS Misses Estimates as Losses WidenBasic EPS Analysis - newsline.com
CV Q1 2026 Earnings: EPS Misses Estimates but Stock Gains 1.95%EPS Consistency Score - newsline.com
CapsoVision Inc. (CV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CapsoVision Inc. (CV) Edges Higher Amid Consolidation – Key Levels to WatchReversal Setup Alerts - The Legal Advocate
CV Q1 2026 Earnings: EPS Misses Estimates Amidst Market HeadwindsEarnings Momentum Score - newsline.com
CapsoVision (CV) Edges Higher, Consolidating Between Key LevelsKAMA Signal - newsline.com
CV Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesNet Profit Margin - The Legal Advocate
CapsoVision Stock Edges Higher as FDA AI Decision Becomes the Real Test - Bez Kabli
CV Q1 2026 Earnings: EPS Misses Estimates as Stock DeclinesGuidance vs Actual - thelegaladvocate.com
CV Q1 2026 Earnings: EPS Misses Estimates Amidst Challenging QuarterInterim Report - newsline.com
CV Q1 2026 Earnings: EPS Misses Estimates by 12%, Stock Declines Nearly 2%Pre-Earnings Setup - newsline.com
CapsoVision (CV) Q1 2026 Earnings: EPS Miss Raises Concerns Amid Operational UncertaintyProfitability Analysis - Newser
CapsoVision Inc. (CV) Gains 1.77% as Shares Test Key Resistance Near $7.23Community Pattern Alerts - Newser
CapsoVision Inc. (CV) Advances 1.18% as Price Moves Toward ResistanceMedian Line - The Legal Advocate
CapsoVision (CV) Q1 2026 Miss: What Went WrongConsensus Beat Rate - Newser
CapsoVision expects AI-assisted reading clearance around midyear, with CapsoCam Colon Gen 2 imaging and AI module targeted for Q3 2026 - MSN
UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
U.S. Smart Pills Market to Reach USD 619.10 Million by 2033 as - openPR.com
CapsoVision, Inc. (CV) AI-Powered Stock Analysis - Meyka
CapsoVision Reports Stable Q1 Revenue and Expands AI Medical Pipeline - HarianBasis.co
Benchmark reiterates Speculative Buy on CapsoVision stock at $10 - Investing.com UK
Benchmark reiterates Speculative Buy on CapsoVision stock at $10 By Investing.com - Investing.com South Africa
CapsoVision Q1 Earnings Call Highlights - sharewise.com
CapsoVision Inc (NASDAQ:CV) Q1 2026 Miss Sends Stock Down 8% in After-Hours Trading - ChartMill
CAPSOVISION ($CV) Releases Q1 2026 Earnings - Quiver Quantitative
Finanzdaten der Capsovision Inc-Aktie (CV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Capsovision Inc-Aktie (CV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Atkinson Douglas Patrick | Head of Global Sales |
May 05 '26 |
Option Exercise |
0.57 |
34,786 |
19,692 |
107,357 |
| Harari Michele | Director |
Dec 31 '25 |
Option Exercise |
10.69 |
2,887 |
30,862 |
59,043 |
| GOUW JULIA S | Director |
Dec 31 '25 |
Option Exercise |
10.69 |
2,887 |
30,862 |
2,887 |
| Imperial Joanne Carol | Director |
Dec 31 '25 |
Option Exercise |
10.69 |
2,887 |
30,862 |
2,887 |
| King Wen-Herng Henry | Director |
Dec 31 '25 |
Option Exercise |
10.69 |
2,887 |
30,862 |
23,597 |
| Kuo Hui Ying | Director |
Dec 31 '25 |
Option Exercise |
10.69 |
2,887 |
30,862 |
13,241 |
| Tsai Chen Lung | Director |
Dec 31 '25 |
Option Exercise |
10.69 |
2,887 |
30,862 |
2,887 |
| Petersen Rebecca Ann | Director of Clinical Affairs |
Aug 18 '25 |
Option Exercise |
0.37 |
24,834 |
9,097 |
24,834 |
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):